Teclistamab in Relapsed or Refractory Multiple Myeloma,The New England Journal of Medicine

当前位置： X-MOL 学术 › N. Engl. J. Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Teclistamab in Relapsed or Refractory Multiple Myeloma
The New England Journal of Medicine ( IF 158.5 ) Pub Date : 2022-06-05 , DOI: 10.1056/nejmoa2203478
Philippe Moreau ₁ , Alfred L Garfall ₁ , Niels W C J van de Donk ₁ , Hareth Nahi ₁ , Jesús F San-Miguel ₁ , Albert Oriol ₁ , Ajay K Nooka ₁ , Thomas Martin ₁ , Laura Rosinol ₁ , Ajai Chari ₁ , Lionel Karlin ₁ , Lotfi Benboubker ₁ , Maria-Victoria Mateos ₁ , Nizar Bahlis ₁ , Rakesh Popat ₁ , Britta Besemer ₁ , Joaquín Martínez-López ₁ , Surbhi Sidana ₁ , Michel Delforge ₁ , Lixia Pei ₁ , Danielle Trancucci ₁ , Raluca Verona ₁ , Suzette Girgis ₁ , Shun X W Lin ₁ , Yunsi Olyslager ₁ , Mindy Jaffe ₁ , Clarissa Uhlar ₁ , Tara Stephenson ₁ , Rian Van Rampelbergh ₁ , Arnob Banerjee ₁ , Jenna D Goldberg ₁ , Rachel Kobos ₁ , Amrita Krishnan ₁ , Saad Z Usmani ₁

Affiliation

From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d'Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d'Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) - all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) - both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d'Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona (A.O.), Hospital Clínic, August Pi i Sunyer Biomedical Research Institute, University of Barcelona, Barcelona (L.R.), University Hospital of Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro del Investigación del Cáncer, CIBERONC, Salamanca (M.-V.M.), and Hematological Malignancies Clinical Research Unit, Hospital 12 de Octubre Universidad Complutense, Centro Nacional de Investigaciones Oncológicas, CIBERONC, Madrid (J.M.-L.) - all in Spain; Winship Cancer Institute, Emory University, Atlanta (A.K.N.); the University of California, San Francisco, San Francisco (T.M.), Stanford University School of Medicine, Stanford (S.S.), and City of Hope Comprehensive Cancer Center, Duarte (A.K.) - all in California; Mount Sinai School of Medicine (A.C.) and Memorial Sloan Kettering Cancer Center (S.Z.U.) - both in New York; Arnie Charbonneau Cancer Institute, University of Calgary, Calgary, AB, Canada (N.B.); Clinical Research Facility, National Institute for Health Research University College London Hospitals, NHS Foundation Trust, London (R.P.); the Department of Hematology, Oncology, and Immunology, University of Tübingen, Tübingen, Germany (B.B.); the University of Leuven, Leuven (M.D.), and Janssen Research and Development, Antwerp (Y.O., R.V.R.) - both in Belgium; Janssen Research and Development, Raritan, NJ (L.P., D.T., M.J., J.D.G., R.K.); and Levine Cancer Institute-Atrium Health, Charlotte, NC (S.Z.U.).

New England Journal of Medicine, Ahead of Print.

中文翻译：